DE69528039D1 - Inhibitoren der fettsäuresynthese als antimikrobielle mittel - Google Patents

Inhibitoren der fettsäuresynthese als antimikrobielle mittel

Info

Publication number
DE69528039D1
DE69528039D1 DE69528039T DE69528039T DE69528039D1 DE 69528039 D1 DE69528039 D1 DE 69528039D1 DE 69528039 T DE69528039 T DE 69528039T DE 69528039 T DE69528039 T DE 69528039T DE 69528039 D1 DE69528039 D1 DE 69528039D1
Authority
DE
Germany
Prior art keywords
fatty acid
acid synthesis
inhibitors
fas
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69528039T
Other languages
English (en)
Other versions
DE69528039T2 (de
Inventor
D Dick
P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE69528039D1 publication Critical patent/DE69528039D1/de
Application granted granted Critical
Publication of DE69528039T2 publication Critical patent/DE69528039T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69528039T 1994-01-24 1995-01-24 Inhibitoren der fettsäuresynthese als antimikrobielle mittel Expired - Fee Related DE69528039T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/188,421 US5614551A (en) 1994-01-24 1994-01-24 Inhibitors of fatty acid synthesis as antimicrobial agents
PCT/US1995/000544 WO1995019706A1 (en) 1994-01-24 1995-01-24 Inhibitors of fatty acid synthesis as antimicrobial agents

Publications (2)

Publication Number Publication Date
DE69528039D1 true DE69528039D1 (de) 2002-10-10
DE69528039T2 DE69528039T2 (de) 2003-08-07

Family

ID=22693071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528039T Expired - Fee Related DE69528039T2 (de) 1994-01-24 1995-01-24 Inhibitoren der fettsäuresynthese als antimikrobielle mittel

Country Status (13)

Country Link
US (1) US5614551A (de)
EP (1) EP0738107B1 (de)
JP (1) JPH09508370A (de)
KR (1) KR100395601B1 (de)
AT (1) ATE223215T1 (de)
AU (1) AU703272B2 (de)
CA (1) CA2181031A1 (de)
DE (1) DE69528039T2 (de)
DK (1) DK0738107T3 (de)
ES (1) ES2182888T3 (de)
MX (1) MX9602934A (de)
PT (1) PT738107E (de)
WO (1) WO1995019706A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010881A (en) * 1996-02-20 2000-01-04 Smithkline Beecham Corporation RibG
US5859027A (en) * 1996-02-26 1999-01-12 Chektec Corporation Antimicrobial agent
US5910509A (en) * 1996-06-20 1999-06-08 Broedel; Sheldon E. Antimicrobial agent for agriculture
WO1998003661A2 (en) * 1996-07-19 1998-01-29 Arch Development Corporation Antimicrobial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
WO1998006734A1 (en) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
US20050112713A1 (en) * 1996-08-28 2005-05-26 Affinium Pharmaceuticals, Inc. Methods of using Fab I and compounds modulating Fab I activity
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5859028A (en) * 1997-04-28 1999-01-12 Potomax Limited Partnership Carotenoid synthesis inhibiting herbicides and fatty acid synthesis inhibiting oxime herbicides as anti-Apicomplexa protozoan parasite agents
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6713654B1 (en) * 1997-08-29 2004-03-30 The Johns Hopkins University School Of Medicine Antimicrobial compounds
PT1007509E (pt) * 1997-08-29 2004-07-30 Univ Johns Hopkins Compostos antimicrobioticos
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US7279007B2 (en) * 1999-08-09 2007-10-09 Cardioklnetix, Inc. Method for improving cardiac function
WO2001014362A1 (en) * 1999-08-23 2001-03-01 Smithkline Beecham Corporation Fatty acid synthase inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
AU773218B2 (en) * 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
WO2001030988A1 (en) * 1999-10-27 2001-05-03 Smithkline Beecham Corporation Methods for making and using fatty acid synthesis pathway reagents
US6656703B1 (en) * 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
US6475751B2 (en) * 2000-01-07 2002-11-05 Virginia Commonwealth University Scintillation proximity assay for type II fatty acid biosynthetic enzymes
US20040157918A1 (en) * 2001-02-16 2004-08-12 Loftus Thomas M. Weight loss induced by reduction in neuropeptide y level
WO2001060174A2 (en) * 2000-02-16 2001-08-23 The Johns Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
WO2001071045A2 (en) * 2000-03-23 2001-09-27 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
US7048926B2 (en) * 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
US7323186B2 (en) * 2001-11-21 2008-01-29 Kimberly-Clark Worldwide, Inc. Non-absorbent articles containing additives
US6821999B2 (en) * 2001-11-21 2004-11-23 Kimberly-Clark Worldwide, Inc. Methods for inhibiting the production of TSST-1
US7348023B2 (en) * 2001-11-21 2008-03-25 Kimberly-Clark Worldwide, Inc. Absorbent articles containing additives
US6955890B2 (en) * 2002-02-14 2005-10-18 Pyro Pharmaceuticals, Inc. Method for the identification and treatment of pathogenic microorganisms infections by inhibiting one or more enzymes in an essential metabolic pathway
US20060063224A1 (en) * 2002-05-10 2006-03-23 Schechter Alan M Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway
BRPI0312649A2 (pt) 2002-07-09 2017-05-16 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2005005469A2 (en) * 2003-07-11 2005-01-20 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
AU2005249437A1 (en) * 2004-05-26 2005-12-15 Fasgen, Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2007053131A2 (en) * 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US20070244199A1 (en) * 2006-02-08 2007-10-18 Fasgen Inc. Anti-mycobacterial formulation
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CA2687964A1 (en) * 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
BR102012033811A8 (pt) * 2012-12-28 2019-12-24 Uniao Brasileira De Educacao E Assistencia Mantenedora Da Puc Rs compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha
BR102013006007A2 (pt) * 2013-03-13 2014-11-11 Ubea Compostos, uso, composição farmacêutica inibidora de redutase em microorganismos, ligante de inha, e, método para obtenção de ligantes de inha a partir de derivados de acetamida, ureia, fenol e carboxamida
MX2018010254A (es) 2016-02-26 2018-12-19 Debiopharm Int Sa Medicamento para el tratamiento de infecciones de pie diabetico.
EP3266454A1 (de) * 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc-hemmer zur verwendung bei der behandlung von mycobakteriellen erkrankungen
US20210137934A1 (en) * 2017-03-16 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying myc-driven and lipogenesis-dependent neoplasms and methods of treating the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE252616C (de) * 1912-01-25 1912-10-23 Gebr Lesser Ablegerad für Kartoffelerntemaschinen mit einem quer zur Fahrrichtung de Maschine umlaufenden Wurfrad
US3535309A (en) * 1967-09-01 1970-10-20 Kitasato Inst Antibiotics and their production
US3630846A (en) * 1967-09-01 1971-12-28 Kitasato Inst And Toyo Jozo Kk Antibiotic production using streptomyces kitasatoensis
US3909361A (en) * 1971-06-29 1975-09-30 Nihon Tokushu Noyaku Seizo Kk Novel antifungal antibiotic substance, process for production of the same, and agricultural and horticultural fungicidal composition containing said substance
JPS5619344B2 (de) * 1972-11-11 1981-05-07
US4011334A (en) * 1975-10-03 1977-03-08 Richardson-Merrell Inc. Use of substituted furan and thiophene carboxaldehydes as hypolipidemic agents
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4738984A (en) * 1973-04-02 1988-04-19 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4000164A (en) * 1973-04-02 1976-12-28 Richardson-Merrell Inc. Hypolipidemic agents
US4032647A (en) * 1975-06-16 1977-06-28 Richardson-Merrell Inc. Substituted thenoylacetic acid and esters
US4110351A (en) * 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
US4328246A (en) * 1979-08-14 1982-05-04 Joseph Gold Anti Walker 256 carcinoma agent and combination thereof
JPS59225115A (ja) * 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS6058917A (ja) * 1983-09-09 1985-04-05 Rikagaku Kenkyusho 制癌剤
FR2552879B1 (fr) * 1983-10-03 1987-08-14 Pasteur Institut Procede et reactifs pour la detection d'une anomalie genetique dans une matiere biologique, notamment dans une preparation de leucocytes
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5110731A (en) * 1985-08-26 1992-05-05 Amgen, Inc. System for biotin synthesis
US4789630A (en) * 1985-10-04 1988-12-06 Cetus Corporation Ionic compounds containing the cationic meriquinone of a benzidine
GB8607137D0 (en) * 1986-03-21 1986-04-30 Efamol Ltd Compositions
US5185149A (en) * 1987-03-27 1993-02-09 Merck & Co., Inc. Methods for thrombolytic therapy
US5188830A (en) * 1987-03-27 1993-02-23 Merck & Co., Inc. Methods for thrombolytic therapy
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
JPH01132542A (ja) * 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
JPH02113850A (ja) * 1988-10-21 1990-04-26 Nippon Oil & Fats Co Ltd 発癌抑制用油脂組成物
US5190969A (en) * 1988-12-20 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents
AU621434B2 (en) * 1988-12-21 1992-03-12 Merrell Dow Pharmaceuticals Inc. Antiretroviral furan ketones
JPH02247125A (ja) * 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
US5143907A (en) * 1991-05-10 1992-09-01 Boron Biologicals, Inc. Phosphite-borane compounds, and method of making and using the same
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0625207A1 (de) * 1991-12-17 1994-11-23 The Regents Of The University Of California Gentherapie zur behandlung der regulatoraktivität der transmembranen leitfähigkeit bei der zytischen fibrose (cftr)
KR100325766B1 (ko) * 1992-07-24 2002-07-27 더 존스 홉킨스 유니버시티 암치료를위한지방산합성억제제를함유하는약학조성물
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition

Also Published As

Publication number Publication date
JPH09508370A (ja) 1997-08-26
EP0738107B1 (de) 2002-09-04
ATE223215T1 (de) 2002-09-15
AU703272B2 (en) 1999-03-25
MX9602934A (es) 1997-12-31
KR100395601B1 (ko) 2003-11-17
PT738107E (pt) 2003-01-31
AU1726895A (en) 1995-08-08
EP0738107A4 (de) 1998-09-09
DE69528039T2 (de) 2003-08-07
US5614551A (en) 1997-03-25
CA2181031A1 (en) 1995-07-27
ES2182888T3 (es) 2003-03-16
EP0738107A1 (de) 1996-10-23
WO1995019706A1 (en) 1995-07-27
DK0738107T3 (da) 2003-01-06

Similar Documents

Publication Publication Date Title
DE69528039D1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
DE69907508T2 (de) Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
AU2002238737A1 (en) Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
AU3887797A (en) Pentafluorobenzenesulfonamides and analogs
PL340551A1 (en) Derivatives of hydroxamic and carboxylic acids exhibiting mmp & tnf inhibitive action
AU7437494A (en) A novel physiologically active substance
ATE225167T1 (de) Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs
HK1059439A1 (en) Compounds having activity as inhibitors of cytochrome p450rai
EP0832100A4 (de) Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
AU2001245319A1 (en) Methods of treating diseases with activated protein c
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
DE69630523D1 (de) Verwendung von Calciumkanalanantagonisten zur Behandlung von Herz-, Nieren-, Magen-und Darmkrankheiten sowie Bluthochdruck
ES2164013A1 (es) Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
TW200503624A (en) Preventive for plant disease and a method for preventing plant disease using the same
SE9903609D0 (sv) Novel compounds I
DE602004015831D1 (de) Verwendung von idrocilamid zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von rosacea

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee